Back

Low utilization of GLP-1RAs and SGLT2i in high-risk cardiovascular patients with diabetes: nationwide insights from myocardial Infarction and stroke survivors

1 September 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Secondary prevention Secondary Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Michal Vrablik

Charles University of Prague, Prague (Czechia)

10 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor L. Heitmann (Reykjavik, IS)
Abstract Slides Video
Presentation thumbnail
Doctor A. Maloberti (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Mrs L. Corteville (Manchester, GB)
Abstract Slides Video
Presentation thumbnail
Doctor V. Oettinger (Freiburg, DE)
Abstract

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Secondary prevention

The Event

Event poster

ESC Congress 2025

1 September 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Presentation
Baseline characteristics and clinical outcomes of patients with type 2 diabetes and cardiovascular disease treated with GLP-1 receptor agonists and SGLT2 inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources